Who
Joshua B. Muntner
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Cardiff Oncology; SVP Business Development, Contrafect.
In numbers
- Trades disclosed
- 6
- Buys
- 1
- Sells
- 0
- Bought
- $2,480
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 25 Jul 2017
- Last trade
- 6 Apr 2026
- Last filed
- 16 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Apr 2026filed 16 Apr 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —486,650 at $0.00 | filing |
| 6 Apr 2026filed 16 Apr 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —486,650 at $0.00 | filing |
| 6 Apr 2026filed 16 Apr 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —486,650 at $0.00 | filing |
| 6 Apr 2026filed 16 Apr 2026 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —486,650 at $0.00 | filing |
| 25 Jul 2017filed 26 Jul 2017 | Contrafect | SEC FORM 4 Bought | $2,4802,000 at $1.24 | filing |
| 25 Jul 2017filed 26 Jul 2017 | Contrafectoption or derivative | SEC FORM 4 Code P | $101,000 at $0.01 | filing |
News
No headline names them, or the companies they trade most, lately.